Divi S Laboratories Q4fy23 Net Profits Down 64 Yoy At Rs321 Crore On Lower Sales And Supply Chain Constraints

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Divi’s Laboratories Q4FY23 net profits down -64% yoy at Rs321 crore on lower sales and supply chain constraints

ri-calendar-2-lineMay 20, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Divi’s Laboratories reported -22.54% lower sales revenues for the March 2023 quarter on consolidated basis at Rs1,951. Revenues were up 14.24% sequentially. The sharp fall in the sales revenues is most likely attributed to the near zero sales of the anti-COVID treatment drug manufactured by Divi’s Laboratories (Molnupiravir). It also saw pressure on pricing in its core business of APIs (active pharma ingredients) and nutraceuticals.

The sharp fall in operating profits by -61% was largely on account of a double whammy. The costs could not be absorbed properly due to sharply lower sales revenues in the quarter. At the same time, the company also saw pressure on profits from higher raw material costs created by supply chain constraints continuing in many cases. Even for the full year FY23, the total revenues at Rs8,112 crore were lower than Rs9,074 crore in FY22.

Financial highlights for Mar-23 compared yoy and sequentially

 Divi's Laboratories    

Rs in Crore

Mar-23

Mar-22

YOY

Dec-22

QOQ

Total Income (Rs cr)

₹ 1,951

₹ 2,518

-22.54%

₹ 1,708

14.24%

Operating Profit (Rs cr)

₹ 401

₹ 1,023

-60.86%

₹ 322

24.59%

Net Profit (Rs cr)

₹ 321

₹ 895

-64.12%

₹ 307

4.62%

 

 

 

 

 

 

Diluted EPS (Rs)

₹ 12.09

₹ 33.70

 

₹ 11.56

 

OPM

20.53%

40.64%

 

18.83%

 

Net Margins

16.45%

35.52%

 

17.97%

 

 

For the fourth quarter, Divi’s Laboratories saw operating margins contract from 40.64% to 20.53% yoy while the net profit margins also contracted from 35.52% to 16.45% yoy. The company has declared dividend of Rs30 per share on face value of Rs2 per share, translating into dividend of 1,500%. Net cash from operations were higher on working capital tweaks.

Related News

News Thumbnail
Quarterly Result

BLS's Q2FY24 Financial Performance Review

2 mins read. November 6, 2023 at 08:56 AM

News Thumbnail
Quarterly Result

Interglobe Aviation's Q2FY24 Financial Performance Review

2 mins read. November 3, 2023 at 11:31 AM

News Thumbnail
Quarterly Result

Titan's Q2FY24 Financial Performance Review

2 mins read. November 3, 2023 at 10:59 AM

News Thumbnail
Quarterly Result

Zomato's Q2FY24 Financial Performance Review

3 mins read. November 3, 2023 at 09:50 AM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions